Furthermore, ATXN2 plays a pathogenic role as a phenotypic modifier in frontotemporal lobar degeneration (FTLD), with associations observed between CAG repeat amplification in ATXN2 and the age of onset of FTLD, as well as the manifestation of Parkinson's syndrome and psychotic symptoms [12]. Here, ATXN2 is linked to frontotemporal dementia.